Georgia Retina

Georgia Retina is a specialized practice focused on diagnosing and treating a range of retinal conditions, providing advanced eye care services and surgical interventions to enhance patient outcomes. Founded in 1994 by Michael Jacobson in Atlanta, US, Georgia Retina is dedicated to the treatment of retinal diseases. The practice has maintained its focus on patient care with no known pivots in its business strategy. Georgia Retina was acquired by EyeSouth Partners in August 2017, although financial terms were not disclosed.

Georgia Retina specializes in the diagnosis and treatment of various retinal conditions, offering comprehensive eye care, surgical interventions, and advanced diagnostic testing. Their core offerings focus on treating conditions such as Age-Related Macular Degeneration (AMD), diabetic retinopathy, retinal detachment, and central serous retinopathy, among others. The practice operates a state-of-the-art Ambulatory Surgery Center, accredited by The American Association for Accreditation of Ambulatory Surgical Facilities. They cater to patients across Metro Atlanta and Northern Georgia, addressing a spectrum of retinal health challenges for both older adults and younger patients.

Georgia Retina generates revenue primarily through direct patient consultations, surgical procedures, and specialized treatments for retinal diseases. The transactional structure is predominantly B2C, as patients schedule appointments directly for diagnostic assessments and therapeutic interventions. Revenues are bolstered by partnerships with healthcare providers and referrals from general ophthalmologists, ensuring a consistent flow of patients seeking specialized retinal care. Georgia Retina’s growth strategy involves leveraging recent funding to enhance its service offerings and expand its geographical reach.

The acquisition by EyeSouth Partners in August 2017 is expected to provide resources for developing new retinal treatment protocols and possibly expanding into new markets within the Southeastern US. While specific new products or services are under consideration, the focus remains on strengthening their operational capacity to increase patient engagement and retention.